TapewireFind a company

person · Reporting owner

Ruffo Frank

Disclosed activity across 1 company

Tapewire entity
129141
SEC CIK
0001654450

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Aclaris Therapeutics, Inc.ACRS · Entity 5041Chief Financial OfficerMarch 10, 2022March 14, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aclaris Therapeutics, Inc.

Report date March 10, 2022 · Filed March 14, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect201,883 Reported balance After 2022-03-10 transaction · row 1
1 source row

Row 1 · 2022-03-10 · Sale · Disposed 12,823 · Balance 201,883

F1: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2022 and March 2, 2022 pursuant to preexisting sell-to-cover elections.

F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.22 to $16.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2022 and March 2, 2022 pursuant to preexisting sell-to-cover elections.

F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.22 to $16.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 10, 2022 Filed Mar 14, 2022 20:56 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 SaleCommon Stock 12,823 $15.55 $199,334.82
Disclosure

SEC source: 0001209191-22-018509 · doc4.xml · nonDerivative · entry 1

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 201,883

F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2022 and March 2, 2022 pursuant to preexisting sell-to-cover elections.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.22 to $16.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
March 02, 2022 Filed Mar 3, 2022 23:08 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionRestricted stock units · Derivative 8,297 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-015809 · doc4.xml · derivative · entry 8

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,595

Underlying: Common Stock · 8,297 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F6 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

F6 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

Read SEC document
March 02, 2022 Filed Mar 3, 2022 23:08 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionCommon Stock 8,297 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-015809 · doc4.xml · nonDerivative · entry 3

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 214,706

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 23:08 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionRestricted stock units · Derivative 8,300 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-015809 · doc4.xml · derivative · entry 7

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,900

Underlying: Common Stock · 8,300 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F5 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

F5 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 23:08 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionRestricted stock units · Derivative 25,750 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-015809 · doc4.xml · derivative · entry 6

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,750

Underlying: Common Stock · 25,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F4 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

F4 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 23:08 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 GrantRestricted stock units · Derivative 44,300 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-015809 · doc4.xml · derivative · entry 5

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,300

Underlying: Common Stock · 44,300 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date.

F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 23:08 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 GrantEmployee Stock Option (Right to Buy) · Derivative 155,200 $0.00 Strike: $14.94 $0.00
Disclosure

SEC source: 0001209191-22-015809 · doc4.xml · derivative · entry 4

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,200

Underlying: Common Stock · 155,200 shares

Expires 2032-02-29

F2 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting in four equal annual installments beginning on March 1, 2023, subject to Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 23:08 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionCommon Stock 8,300 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-015809 · doc4.xml · nonDerivative · entry 2

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 206,409

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 23:08 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionCommon Stock 25,750 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-015809 · doc4.xml · nonDerivative · entry 1

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 198,109

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

Read SEC document
February 09, 2022 Filed Feb 11, 2022 21:18 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 SaleCommon Stock 1,388 $12.66 $17,568.47
Disclosure

SEC source: 0001209191-22-008849 · doc4.xml · nonDerivative · entry 1

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 172,359

F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on February 1, 2022 pursuant to preexisting sell-to-cover elections.

Read SEC document
February 01, 2022 Filed Feb 3, 2022 21:46 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionRestricted Stock Units · Derivative 3,875 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-006832 · doc4.xml · derivative · entry 2

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,875 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F2 · derivative.exercise_date: The shares underlying these restricted stock units vested on February 1, 2022.

F2 · derivative.expiration_date: The shares underlying these restricted stock units vested on February 1, 2022.

Read SEC document
February 01, 2022 Filed Feb 3, 2022 21:46 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionCommon Stock 3,875 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-006832 · doc4.xml · nonDerivative · entry 1

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 173,747

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

Read SEC document
June 02, 2021 Filed Jun 3, 2021 01:43 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 SaleCommon Stock 2,450 $22.30 $54,635.00
Disclosure

SEC source: 0001209191-21-037475 · doc4.xml · nonDerivative · entry 3

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,872

F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.06 to $22.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 02, 2021 Filed Jun 3, 2021 01:43 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 SaleCommon Stock 12,587 $21.51 $270,747.63
Disclosure

SEC source: 0001209191-21-037475 · doc4.xml · nonDerivative · entry 2

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 172,322

F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.06 to $22.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 01, 2021 Filed Jun 3, 2021 01:43 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionRestricted Stock Units · Derivative 33,189 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-037475 · doc4.xml · derivative · entry 4

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 33,189 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F5 · derivative.exercise_date: The shares underlying these restricted stock units vested in two equal annual installments beginning on June 1, 2020.

F5 · derivative.expiration_date: The shares underlying these restricted stock units vested in two equal annual installments beginning on June 1, 2020.

Read SEC document
June 01, 2021 Filed Jun 3, 2021 01:43 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionCommon Stock 33,189 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-037475 · doc4.xml · nonDerivative · entry 1

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 184,909

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

Read SEC document
April 26, 2021 Filed Apr 27, 2021 01:45 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 SaleCommon Stock 100 $26.44 $2,644.00
Disclosure

SEC source: 0001209191-21-028453 · doc4.xml · nonDerivative · entry 5

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,720

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021.

Read SEC document
April 26, 2021 Filed Apr 27, 2021 01:45 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 SaleCommon Stock 27,239 $25.79 $702,583.70
Disclosure

SEC source: 0001209191-21-028453 · doc4.xml · nonDerivative · entry 4

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,820

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021.

F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.38 to $26.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
April 23, 2021 Filed Apr 27, 2021 01:45 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 SaleCommon Stock 800 $27.33 $21,862.96
Disclosure

SEC source: 0001209191-21-028453 · doc4.xml · nonDerivative · entry 3

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 179,059

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $27.23 to $27.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
April 23, 2021 Filed Apr 27, 2021 01:45 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 SaleCommon Stock 29,200 $26.64 $777,797.48
Disclosure

SEC source: 0001209191-21-028453 · doc4.xml · nonDerivative · entry 2

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 179,859

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.23 to $27.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
April 22, 2021 Filed Apr 27, 2021 01:45 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 SaleCommon Stock 30,000 $26.84 $805,218.00
Disclosure

SEC source: 0001209191-21-028453 · doc4.xml · nonDerivative · entry 1

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 209,059

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.51 to $27.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
March 02, 2021 Filed Mar 4, 2021 01:36 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionRestricted stock units · Derivative 8,297 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-017533 · doc4.xml · derivative · entry 8

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,892

Underlying: Common Stock · 8,297 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F6 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

F6 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

Read SEC document
March 02, 2021 Filed Mar 4, 2021 01:36 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Tax withholdingCommon Stock 2,844 $23.25 $66,123.00
Disclosure

SEC source: 0001209191-21-017533 · doc4.xml · nonDerivative · entry 4

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 239,059

F2 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4.

Read SEC document
March 02, 2021 Filed Mar 4, 2021 01:36 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionCommon Stock 8,297 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-017533 · doc4.xml · nonDerivative · entry 3

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 241,903

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

Read SEC document
March 01, 2021 Filed Mar 4, 2021 01:36 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionRestricted stock units · Derivative 25,750 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-017533 · doc4.xml · derivative · entry 7

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,500

Underlying: Common Stock · 25,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F5 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

F5 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

Read SEC document
March 01, 2021 Filed Mar 4, 2021 01:36 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 GrantRestricted stock units · Derivative 33,200 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-017533 · doc4.xml · derivative · entry 6

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,200

Underlying: Common Stock · 33,200 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F4 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

F4 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

Read SEC document
March 01, 2021 Filed Mar 4, 2021 01:36 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 GrantEmployee Stock Option (Right to Buy) · Derivative 116,000 $0.00 Strike: $24.06 $0.00
Disclosure

SEC source: 0001209191-21-017533 · doc4.xml · derivative · entry 5

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,000

Underlying: Common Stock · 116,000 shares

Expires 2031-02-28

F3 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting on each of the first, second, third and fourth anniversaries of the grant date, subject to Reporting Person's continuous service through each such date.

Read SEC document
March 01, 2021 Filed Mar 4, 2021 01:36 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Tax withholdingCommon Stock 7,333 $24.06 $176,431.98
Disclosure

SEC source: 0001209191-21-017533 · doc4.xml · nonDerivative · entry 2

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 233,606

F2 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4.

Read SEC document
March 01, 2021 Filed Mar 4, 2021 01:36 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionCommon Stock 25,750 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-017533 · doc4.xml · nonDerivative · entry 1

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 240,939

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

Read SEC document
February 01, 2021 Filed Feb 3, 2021 22:29 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionRestricted Stock Units · Derivative 3,875 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-007375 · doc4.xml · derivative · entry 3

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,875

Underlying: Common Stock · 3,875 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

Read SEC document
February 01, 2021 Filed Feb 3, 2021 22:29 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Tax withholdingCommon Stock 1,308 $21.35 $27,925.80
Disclosure

SEC source: 0001209191-21-007375 · doc4.xml · nonDerivative · entry 2

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 215,189

F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4.

Read SEC document
February 01, 2021 Filed Feb 3, 2021 22:29 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionCommon Stock 3,875 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-007375 · doc4.xml · nonDerivative · entry 1

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 216,497

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
December 15, 2020 Filed Dec 17, 2020 22:07 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionRestricted Stock Units · Derivative 1,300 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-064126 · doc4.xml · derivative · entry 3

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,300 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: On December 15, 2016, the reporting person was granted 10,400 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vested in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

F3 · derivative.expiration_date: On December 15, 2016, the reporting person was granted 10,400 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vested in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

Read SEC document
December 15, 2020 Filed Dec 17, 2020 22:07 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Tax withholdingCommon Stock 370 $4.59 $1,698.30
Disclosure

SEC source: 0001209191-20-064126 · doc4.xml · nonDerivative · entry 2

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 212,622

F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4.

Read SEC document
December 15, 2020 Filed Dec 17, 2020 22:07 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionCommon Stock 1,300 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-064126 · doc4.xml · nonDerivative · entry 1

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 212,992

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
June 01, 2020 Filed Jun 3, 2020 20:45 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionRestricted stock units · Derivative 33,188 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-034068 · doc4.xml · derivative · entry 3

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,189

Underlying: Common Stock · 33,188 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

Read SEC document
June 01, 2020 Filed Jun 3, 2020 20:45 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Tax withholdingCommon Stock 9,451 $1.32 $12,475.32
Disclosure

SEC source: 0001209191-20-034068 · doc4.xml · nonDerivative · entry 2

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 211,692

F2 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4.

Read SEC document
June 01, 2020 Filed Jun 3, 2020 20:45 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionCommon Stock 33,188 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-034068 · doc4.xml · nonDerivative · entry 1

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 221,143

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

Read SEC document
March 02, 2020 Filed Mar 4, 2020 21:30 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 GrantRestricted stock units · Derivative 33,189 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-016092 · doc4.xml · derivative · entry 6

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,189

Underlying: Common Stock · 33,189 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F6 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

F6 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

Read SEC document
March 02, 2020 Filed Mar 4, 2020 21:30 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 GrantRestricted stock units · Derivative 66,377 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-016092 · doc4.xml · derivative · entry 5

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,377

Underlying: Common Stock · 66,377 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F5 · derivative.exercise_date: The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

F5 · derivative.expiration_date: The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

Read SEC document
March 02, 2020 Filed Mar 4, 2020 21:30 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 GrantEmployee Stock Option (Right to Buy) · Derivative 116,160 $0.00 Strike: $1.26 $0.00
Disclosure

SEC source: 0001209191-20-016092 · doc4.xml · derivative · entry 4

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,160

Underlying: Common Stock · 116,160 shares

Expires 2030-03-01

F4 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting on each of the first, second, third and fourth anniversaries of the grant date, subject to Reporting Person's continuous service through each such date.

Read SEC document
March 02, 2020 Filed Mar 4, 2020 21:30 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionRestricted stock units · Derivative 25,750 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-016092 · doc4.xml · derivative · entry 3

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,250

Underlying: Common Stock · 25,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

Read SEC document
March 02, 2020 Filed Mar 4, 2020 21:30 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Tax withholdingCommon Stock 7,162 $1.26 $9,024.12
Disclosure

SEC source: 0001209191-20-016092 · doc4.xml · nonDerivative · entry 2

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,955

F2 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4.

Read SEC document
March 02, 2020 Filed Mar 4, 2020 21:30 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionCommon Stock 25,750 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-016092 · doc4.xml · nonDerivative · entry 1

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 195,117

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

Read SEC document
February 03, 2020 Filed Feb 5, 2020 00:12 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionRestricted Stock Units · Derivative 3,875 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-006667 · doc4.xml · derivative · entry 3

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,750

Underlying: Common Stock · 3,875 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

Read SEC document
February 03, 2020 Filed Feb 5, 2020 00:12 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Tax withholdingCommon Stock 1,308 $1.28 $1,674.24
Disclosure

SEC source: 0001209191-20-006667 · doc4.xml · nonDerivative · entry 2

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,367

F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4.

Read SEC document
February 03, 2020 Filed Feb 5, 2020 00:12 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionCommon Stock 3,875 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-006667 · doc4.xml · nonDerivative · entry 1

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,675

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
December 18, 2019 Filed Dec 20, 2019 21:18 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionRestricted Stock Units · Derivative 1,250 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-061540 · doc4.xml · derivative · entry 3

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: On December 18, 2015, the reporting person was granted 5,000 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

F3 · derivative.expiration_date: On December 18, 2015, the reporting person was granted 5,000 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

Read SEC document
December 18, 2019 Filed Dec 20, 2019 21:18 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Tax withholdingCommon Stock 356 $1.81 $644.36
Disclosure

SEC source: 0001209191-19-061540 · doc4.xml · nonDerivative · entry 2

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,800

F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4.

Read SEC document
December 18, 2019 Filed Dec 20, 2019 21:18 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionCommon Stock 1,250 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-061540 · doc4.xml · nonDerivative · entry 1

Ruffo Frank · CIK 0001654450 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 167,156

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.